We read with great interest the review titled “Renal protection in heart failure with reduced ejection fraction: not all that glitters is gold” by Elisa Russo and colleagues, published in your journal in 2026. The article provides a systematic overview of the renal outcomes associated with guideline-directed medical therapies in patients with HFrEF and concomitant CKD, with the key conclusion that SGLT2 inhibitors offer unique and robust dual cardiorenal protection, whereas ARNI and novel MRAs, while promising, lack complete evidence [1].
